BGLC VS DFFN Stock Comparison

Performance

BGLC
10/100

BGLC returned -97.12% in the last 12 months. Based on SPY's performance of -13.73%, its performance is below average giving it a score of 10 of 100.

DFFN
10/100

DFFN returned -61.80% in the last 12 months. Based on SPY's performance of -8.71%, its performance is below average giving it a score of 10 of 100.

Profit

BGLC
33/100

Out of the last 18 quarters, BGLC has had 6 profitable quarters and has increased their profits year over year on 4 of them.

DFFN
10/100

Out of the last 20 quarters, DFFN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

BGLC
56/100

BGLC has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

DFFN
48/100

DFFN has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Analyst Price Targets

BGLC

"Analyst Price Targets" not found for BGLC

DFFN
75/100

1 analysts offer 12-month price targets for DFFN. Together, they have an average target of 0, the most optimistic target put DFFN at 0 within 12-months and the most pessimistic has DFFN at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Technicals

BGLC

"Technicals" not found for BGLC

DFFN
14/100

DFFN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

BGLC

"Earnings" not found for BGLC

DFFN
10/100

DFFN has missed earnings 7 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

BioNexus Gene Lab Corp Common stock Summary

Nasdaq / BGLC

Healthcare

Medical - Diagnostics & Research

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

DIFFUSION PHARMACEUTICALS INC Summary

Nasdaq / DFFN

Healthcare

Biotechnology

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Power up your portfolio